医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Release Q3 FY15 Results on January 29, 2015

2015年01月23日 AM12:31
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY) will announce results for the Third Quarter ended December 31, 2014 on Thursday, January 29, 2015 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com.

Summary of Events

Event     Date and Time     Medium
Release of financial results     January 29th, after the Board Meeting     Email, Media, Company website, Businesswire
Earnings Call     January 29th, 6.30 PM IST / 8:00 AM EST    

Hosted by the Company (Details below)

Webcast of Earnings Call     January 29th, 6.30 PM IST / 8.00 AM EST through February 3rd    

URL available on Company’s website, www.drreddys.com

Transcript of the Earnings call     Will be available on the Company’s website    

URL available on Company’s website, www.drreddys.com

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance.

Conference Dial-In Numbers
Primary Number:     +91 22 3960 0616
Secondary Number:     +91 22 6746 5826
The numbers listed above are universally accessible from all networks and all countries.
Local Access Number:     6000 1221
Available in – Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada

Accessible from all major carriers except BSNL/MTNL.

3940 3977

Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune

Accessible from all carriers.

International Toll Free Number:     USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through February 3rd, 2015. For play back dial in phone No: 022 3065 1212 and ID: 375#.

Transcript

The transcript of the earnings call will also be available on the Company’s website.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets.

For more information, log on to: www.drreddys.com

CONTACT

Dr. Reddy’s Laboratories
Investor Relations:
Kedar
Upadhye at kedaru@drreddys.com
/ +91 40 66834297
Saunak Savla at saunaks@drreddys.com
/ +91 40 49002135
Ashish Girotra (USA) at ashishg@drreddys.com/
+1 609-375-9805

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • PotNetwork Holdings, Inc.在注册成为SEC报告公司之后发布PCAOB经审计和审核的完整财务报表
  • PotNetwork Holdings, Inc.提交Form 10以成为美国证券交易委员会报告公司
  • レスメド初の最小接触面フルフェイスCPAPマスクAirFit F30を米国とカナダで販売開始
  • Foundation Medicine Announces Strategic Collaboration with Major Pharmaceutical Company
  • Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market